Literature DB >> 22260667

Regulation of MEK/ERK pathway output by subcellular localization of B-Raf.

Catherine Andreadi1, Catherine Noble, Bipin Patel, Hong Jin, Maria M Aguilar Hernandez, Kathryn Balmanno, Simon J Cook, Catrin Pritchard.   

Abstract

The strength and duration of intracellular signalling pathway activation is a key determinant of the biological outcome of cells in response to extracellular cues. This has been particularly elucidated for the Ras/Raf/MEK [mitogen-activated growth factor/ERK (extracellular-signal-regulated kinase) kinase]/ERK signalling pathway with a number of studies in fibroblasts showing that sustained ERK signalling is a requirement for S-phase entry, whereas transient ERK signalling does not have this capability. A major unanswered question, however, is how a cell can sustain ERK activation, particularly when ERK-specific phosphatases are transcriptionally up-regulated by the pathway itself. A major point of ERK regulation is at the level of Raf, and, to sustain ERK activation in the presence of ERK phosphatases, sustained Raf activation is a requirement. Three Raf proteins exist in mammals, and the activity of all three is induced following growth factor stimulation of cells, but only B-Raf activity is maintained at later time points. This observation points to B-Raf as a regulator of sustained ERK activation. In the present review, we consider evidence for a link between B-Raf and sustained ERK activation, focusing on a potential role for the subcellular localization of B-Raf in this key physiological event.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22260667     DOI: 10.1042/BST20110621

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  11 in total

1.  Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.

Authors:  Georgios Antonios Margonis; Stefan Buettner; Nikolaos Andreatos; Yuhree Kim; Doris Wagner; Kazunari Sasaki; Andrea Beer; Christoph Schwarz; Inger Marie Løes; Maria Smolle; Carsten Kamphues; Jin He; Timothy M Pawlik; Klaus Kaczirek; George Poultsides; Per Eystein Lønning; John L Cameron; Richard A Burkhart; Armin Gerger; Federico N Aucejo; Martin E Kreis; Christopher L Wolfgang; Matthew J Weiss
Journal:  JAMA Surg       Date:  2018-07-18       Impact factor: 14.766

Review 2.  PTEN regulation of ERK1/2 signaling in cancer.

Authors:  Mahandranauth A Chetram; Cimona V Hinton
Journal:  J Recept Signal Transduct Res       Date:  2012-06-28       Impact factor: 2.092

3.  Noncanonical mode of ERK action controls alternative αβ and γδ T cell lineage fates.

Authors:  Sang-Yun Lee; Francis Coffey; Shawn P Fahl; Suraj Peri; Michele Rhodes; Kathy Q Cai; Michael Carleton; Stephen M Hedrick; Hans Joerg Fehling; Juan Carlos Zúñiga-Pflücker; Dietmar J Kappes; David L Wiest
Journal:  Immunity       Date:  2014-11-28       Impact factor: 31.745

4.  Nuclear interaction of Arp2/3 complex and BRAFV600E promotes aggressive behavior and vemurafenib resistance of thyroid cancer.

Authors:  Mourad Zerfaoui; Koji Tsumagari; Eman Toraih; Youssef Errami; Emmanuelle Ruiz; Mohammed Sohail M Elaasar; Moroz Krzysztof; Andrew B Sholl; Sameh Magdeldin; Mohamed Soudy; Zakaria Y Abd Elmageed; A Hamid Boulares; Emad Kandil
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

5.  Receptor cross-talk spatially restricts p-ERK during TLR4 stimulation of autoreactive B cells.

Authors:  Sang-Ryul Lee; Jennifer A Rutan; Andrew J Monteith; Shannon Z Jones; Sun Ah Kang; Kristen N Krum; Michelle A Kilmon; Jose R Roques; Nikki J Wagner; Stephen H Clarke; Barbara J Vilen
Journal:  J Immunol       Date:  2012-09-14       Impact factor: 5.422

Review 6.  MAPKs and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation.

Authors:  Luciana H Osaki; Patrícia Gama
Journal:  Int J Mol Sci       Date:  2013-05-13       Impact factor: 5.923

7.  Extracellular matrix collagen alters cell proliferation and cell cycle progression of human uterine leiomyoma smooth muscle cells.

Authors:  Faezeh Koohestani; Andrea G Braundmeier; Arash Mahdian; Jane Seo; JiaJia Bi; Romana A Nowak
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

8.  Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.

Authors:  Eiji Shinozaki; Takayuki Yoshino; Kentaro Yamazaki; Kei Muro; Kensei Yamaguchi; Tomohiro Nishina; Satoshi Yuki; Kohei Shitara; Hideaki Bando; Sachiyo Mimaki; Chikako Nakai; Koutatsu Matsushima; Yutaka Suzuki; Kiwamu Akagi; Takeharu Yamanaka; Shogo Nomura; Satoshi Fujii; Hiroyasu Esumi; Masaya Sugiyama; Nao Nishida; Masashi Mizokami; Yasuhiro Koh; Yukiko Abe; Atsushi Ohtsu; Katsuya Tsuchihara
Journal:  Br J Cancer       Date:  2017-10-03       Impact factor: 7.640

9.  m6A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling.

Authors:  Jian-Wei Xie; Xiao-Bo Huang; Qi-Yue Chen; Yu-Bin Ma; Ya-Jun Zhao; Li-Chao Liu; Jia-Bin Wang; Jian-Xian Lin; Jun Lu; Long-Long Cao; Mi Lin; Ru-Hong Tu; Chao-Hui Zheng; Chang-Ming Huang; Ping Li
Journal:  Mol Cancer       Date:  2020-07-10       Impact factor: 27.401

10.  Nuclear Localization of BRAFV600E Is Associated with HMOX-1 Upregulation and Aggressive Behavior of Melanoma Cells.

Authors:  Mourad Zerfaoui; Eman Toraih; Emmanuelle Ruiz; Youssef Errami; Abdallah S Attia; Moroz Krzysztof; Zakaria Y Abd Elmageed; Emad Kandil
Journal:  Cancers (Basel)       Date:  2022-01-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.